In MS patients with CMBs, the correlation between CCL18 and PAI1 (r = 0.85, p = 0.001, CI 95% = 0.74, 0.97) was even stronger than in MS patients without CMBs (r = 0.26, p = 0.003, CI 95% = 0.10, 0.42). Here, CCL18 is linked to myeloid sarcoma.